A detailed history of Core Cap Advisors, LLC transactions in Immunovant, Inc. stock. As of the latest transaction made, Core Cap Advisors, LLC holds 7,725 shares of IMVT stock, worth $212,514. This represents 0.02% of its overall portfolio holdings.

Number of Shares
7,725
Previous 6,407 20.57%
Holding current value
$212,514
Previous $269,000 24.54%
% of portfolio
0.02%
Previous 0.02%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 08, 2024

BUY
$25.1 - $31.61 $33,081 - $41,661
1,318 Added 20.57%
7,725 $203,000
Q1 2024

Aug 08, 2024

BUY
$30.27 - $43.79 $9,474 - $13,706
313 Added 4.05%
8,038 $259,000
Q4 2023

Jan 12, 2024

BUY
$31.31 - $44.19 $20,257 - $28,590
647 Added 11.23%
6,407 $269,000
Q3 2023

Jan 12, 2024

SELL
$18.55 - $39.96 $179,044 - $385,693
-9,652 Reduced 62.63%
5,760 $221,000
Q2 2023

Jan 12, 2024

BUY
$14.2 - $23.75 $218,850 - $366,035
15,412 New
15,412 $292,000

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Core Cap Advisors, LLC Portfolio

Follow Core Cap Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Core Cap Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Core Cap Advisors, LLC with notifications on news.